about
A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacologyCytokines in psoriasis.Confirmation of genetic heterogeneity in familial psoriasis.FK 506: a novel immunosuppressant for treatment of autoimmune disease. Rationale and preliminary clinical experience at the University of Pittsburgh.'Activation-induced cell death': a special program able to preserve the homeostasis of the skin?Interleukin-18 expression and the response to treatment in patients with psoriasis.A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice.Tazarotene: a review of its pharmacological profile and potential for clinical use in psoriasis.Potential therapeutic role of peroxisome proliferator activated receptor-gamma agonists in psoriasis.Ultraviolet radiation therapy and UVR dose models.A Review on the Potential Role of Basement Membrane Laminin in the Pathogenesis of Psoriasis.Immunointervention in psoriasis with anti-CD4 antibodies.Epidermal CD8+ T cells in chronic plaque psoriasis are Tc1 cells producing heterogeneous levels of interferon-gamma.Regulatory effects of gamma-interferon on IL-6 and IL-8 secretion by cultured human keratinocytes and dermal fibroblasts.Cytokines, neuropeptides, and other factors in cutaneous immune responses.Cutaneous manipulation of vascular growth factors leads to alterations in immunocytes, blood vessels and nerves: Evidence for a cutaneous neurovascular unit.Interleukin-18 expression and the response to treatment in patients with psoriasis.Effect of propylthiouracil on adenosine deaminase activity and thyroid function in patients with psoriasis.Role of Pityrosporum ovale in guttate psoriasis.Improvement of herpetic stromal keratitis with fumaric acid derivate is associated with systemic induction of T helper 2 cytokines.Possible role of proenkephalin in psoriasis.Production of type-1 and type-2 cytokines by peripheral blood mononuclear cells of psoriatic patientsEvaluation of ADA activity as a potential marker of disease severity in psoriasis patients
P2860
Q28372000-8051772B-38A4-46C4-A5A6-F4BBE6B194ECQ33632263-4C149E1D-9A8C-4CEF-92D8-AD726E901EB6Q33677109-CB8A11DD-86FB-41DD-AB51-C01C0B9B8B48Q34251607-E811BFA9-673A-496E-9F0F-B6AB595D5D8BQ34600681-0EF7C7F2-D50F-4840-9042-D92BA18CA4A6Q35674258-806E466A-CA20-44E8-8037-1043A712ACB5Q35833532-47530A3D-2FF8-44E0-A211-F21393B2250CQ36179670-E654461F-C16F-4141-AEEC-6019B452AA06Q36221953-735E5B22-32D6-4633-B51F-06631A8191F4Q38308916-5679A6D6-5794-41B0-AF42-5C303E49D1BFQ38582500-6E1F8EE2-2C84-47B8-BA17-6C493FA299F5Q40624548-05D86B62-7CC8-45BB-B8FB-4DE3FC662A89Q40802615-C6D1ED97-6C25-446F-9458-BF1F7D6DEB11Q41263411-CF470760-D077-435D-A4F0-C5DFE5EF8E5EQ41840104-363EE8F6-D1BB-467B-84B0-02E565051E38Q42131617-42B88FBC-2294-467B-A885-A3F6D25F4344Q42131904-0A9906D2-F682-4C78-B726-3D2ECEEA0086Q43650476-8BD6B0E7-A51D-4F5B-AA10-233C02383ECDQ44401376-E59A0E4E-2770-481C-B7B7-A64E4D3E5229Q46716300-5D467DE3-E71A-4D5B-88E2-B62BC41CB31BQ53799401-057B2E13-587B-49D3-8426-95B8F9EEDC06Q57997774-23BEE4D8-DF67-4F8D-AD79-2621CDE0A0EFQ58764911-36D8625A-DBD6-42D2-A6FC-8C16D3B20547
P2860
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
The immunology of psoriasis.
@ast
The immunology of psoriasis.
@en
type
label
The immunology of psoriasis.
@ast
The immunology of psoriasis.
@en
prefLabel
The immunology of psoriasis.
@ast
The immunology of psoriasis.
@en
P2860
P1476
The immunology of psoriasis.
@en
P2860
P356
10.1111/J.1365-2133.1992.TB08394.X
P407
P577
1992-01-01T00:00:00Z